États-Unis · Bourse & Finance · The Motley Fool

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Publié par The Motley Fool · États-Unis il y a 11 h

Viking's significant clinical win. Viking Therapeutics ran a study that enrolled approximately 180 patients who took either various doses of its leading pipeline candidate, subcut…

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

À lire aussi

Binance Pay lets visitors spend USDT at PayPay merchants in Japan

Shell-led LNG Canada to proceed with Phase 2 expansion, doubling export capacity

China factory activity snaps 2-month contractionary streak in September

Paramount's streaming chief is out ahead of the WBD merger. Read the memo she sent to staff.

A.I. Is ‘Better Informed’ Than Doctors, Kennedy Tells Industry-Backed MAHA Summit

Oil's New Normal Is Higher Prices

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Partager

À lire aussi

Binance Pay lets visitors spend USDT at PayPay merchants in Japan

Shell-led LNG Canada to proceed with Phase 2 expansion, doubling export capacity

China factory activity snaps 2-month contractionary streak in September

Paramount's streaming chief is out ahead of the WBD merger. Read the memo she sent to staff.

A.I. Is ‘Better Informed’ Than Doctors, Kennedy Tells Industry-Backed MAHA Summit

Oil's New Normal Is Higher Prices